Chat on precision medicine in lung cancer
Last week, the National Cancer Institute (NCI) hosted a Twitter chat on precision medicine in lung cancer. Danielle Shafer, D.O., hematologist-oncologist, member of the Developmental Therapeutics research program at Massey Cancer Center and assistant professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine, provided expert commentary as Dr. Shakun Malik, head of thoracic oncology therapeutics for the NCI’s Cancer Therapy Evaluation Program, posed a series of questions and discussion topics.
Bradley awarded endowed chair
Cathy J. Bradley, Ph.D., associate director for cancer prevention and control at VCU Massey Cancer Center, has been awarded the Theresa A. Thomas Memorial Foundation Chair in Cancer Prevention and Control in recognition of her exemplary contributions to Massey’s research mission. Bradley also serves as program leader for Massey’s Cancer Prevention and Control research program, founding chair of VCU School of Medicine’s Department of Healthcare Policy and Research and interim chair of VCU’s Department of Social and Behavioral Health. She previously held the RGC Professorship in Cancer Research.
Enter the “Mos for Massey” Social Media Contest!
“Movember” is a campaign that encourages men to grow moustaches during the month of November to help raise awareness for testicular cancer, prostate cancer and mental health issues. VCU Massey Cancer Center invites everyone (men, women and kids!) to join the “Movember” movement and help us raise awareness for men’s cancers by taking part in our “Mos for Massey” contest.
Massey and VIMM researchers receive $1.8 million grant to test a promising prostate cancer immunotherapy
Virginia Commonwealth University (VCU) Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) researchers Paul B. Fisher, M.Ph., Ph.D., and Xiang-Yang (Shawn) Wang, Ph.D., have been awarded nearly $1.8 million from the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) to test a promising prostate cancer immunotherapy that leverages tumor-reactive lymphocytes, a type of white blood cell, and a cancer toxic gene. The grant will allow Fisher and Wang to test this novel therapy using preclinical animal models. If successful, the team hopes to translate the research into clinical trials to further test it in patients with metastatic prostate cancer.
VCU Massey Cancer Center becomes the first cancer care provider in Virginia to perform next-generation genome sequencing for precision cancer treatment
VCU Massey Cancer Center has taken precision medicine in Virginia to the next level with the introduction of advanced genomic sequencing for the treatment of cancer. Patients now have in-house access to Oncogenomics DX1, a single test that can sequence their cancer’s DNA and match them with existing or experimental therapies that target the specific molecule or gene driving their disease.